Ascendis Pharma A/S
$
120.89
-1.48 (-1.21%)
| Volume: | 261,157 | Avg Vol (1m): | 286,885 |
| Market Cap $: | 5.69 Bil | Enterprise Value $: | 4.91 Bil |
| P/E (TTM): | 0.00 | P/B: | 6.47 |
| Earnings Power Value | -706.89 |
| Net Current Asset Value | 17.47 |
| Tangible Book | 18.58 |
| Projected FCF | 0 |
| Median P/S Value | 79.45 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
70.59%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ASND:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 68.56, Med: 10000, Max: 10000
Current: 10000
|
| Equity-to-Asset | 0.94 |
Equity-to-Asset ranked
higher than
93.97%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ASND:
0.94
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.16, Med: 0.9, Max: 0.95
Current: 0.94
|
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 68.49 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 8.49 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 0%
WACC 8.02%
| ||
Profitability & Growth : 2/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -1115.33 |
Operating Margin ranked
lower than
92.30%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ASND:
-1115.33
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -7290.26, Med: -515.21, Max: 25.87
Current: -1115.33
|
| Net Margin % | -900.61 |
Net Margin ranked
lower than
93.43%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ASND:
-900.61
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -8097.84, Med: -405.54, Max: 19.99
Current: -900.61
|
| ROE % | -35.49 |
ROE ranked
lower than
63.20%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ASND:
-35.49
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -71.9, Med: -38.24, Max: 139.69
Current: -35.49
|
| ROA % | -32.70 |
ROA ranked
lower than
71.31%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ASND:
-32.7
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -65.14, Med: -33.22, Max: 15.98
Current: -32.7
|
| ROC (Joel Greenblatt) % | -1932.67 |
ROC (Joel Greenblatt) ranked
lower than
79.44%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ASND:
-1932.67
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -5343.32, Med: -1499.83, Max: 303.45
Current: -1932.67
|
| 3-Year Total Revenue Growth Rate | 10.80 |
3-Year Revenue Growth Rate ranked
lower than
86.18%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ASND:
-7.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -58.6, Max: -7.6
Current: -7.6
|
| 3-Year Total EBITDA Growth Rate | -60.00 |
3-Year EBITDA Growth Rate ranked
lower than
93.39%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ASND:
-33.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.3
Current: -33.3
|
| 3-Year EPS w/o NRI Growth Rate | -33.50 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
94.76%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ASND:
-33.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.5
Current: -33.5
|
» ASND's 30-Y Financials
Financials (Next Earnings Date: 2019-08-29)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ASND
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325411   SIC : 2833 |
| Compare | NAS:HALO NAS:CBPO NAS:PBYI SZSE:300009 NAS:ANAB NAS:FOLD NYSE:EBS SHSE:600161 XBRU:ARGX NAS:ACAD SZSE:002821 XSWX:GALE XSWX:IDIA NAS:CRSP NAS:RARE NAS:IMMU SZSE:002603 NAS:CLVS SZSE:000990 HKSE:00570 |
| Traded in other countries | A71.Germany |
| Address | Tuborg Boulevard 5, Hellerup, DNK, DK-2900 |
| Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP etc. It operates mainly in USA, Germany, and Switzerland and derives the majority of its revenue from the US. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 6.47 |
PB Ratio ranked
lower than
67.67%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ASND:
6.47
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.43, Med: 5.5, Max: 10.24
Current: 6.47
|
| PS Ratio | 283.13 |
PS Ratio ranked
lower than
97.25%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ASND:
283.13
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 15.85, Med: 186.06, Max: 5905
Current: 283.13
|
| EV-to-EBIT | -33.74 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ASND:
-33.74
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -37.8, Med: -9.8, Max: -3.6
Current: -33.74
|
| EV-to-EBITDA | -33.97 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ASND:
-33.97
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -38.08, Med: -9.9, Max: -3.6
Current: -33.97
|
| EV-to-Revenue | 407.36 |
EV-to-Revenue ranked
lower than
95.46%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ASND:
407.36
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 15.4, Med: 181.1, Max: 6352.5
Current: 407.36
|
| Current Ratio | 22.32 |
Current Ratio ranked
higher than
91.53%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ASND:
22.32
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
|
| Quick Ratio | 22.32 |
Quick Ratio ranked
higher than
91.53%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ASND:
22.32
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
|
| Days Sales Outstanding | 0.09 |
Days Sales Outstanding ranked
higher than
88.77%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ASND:
0.09
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 0.09, Med: 33.73, Max: 133.93
Current: 0.09
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -17.80 |
3-Year Share Buyback Rate ranked
lower than
73.75%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ASND:
-17.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -44.2, Med: -29.7, Max: 0
Current: -17.8
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.51 |
Price-to-Tangible-Book ranked
lower than
60.40%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ASND:
6.51
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 2.62, Med: 5.54, Max: 8.49
Current: 6.51
|
| Price-to-Median-PS-Value | 1.52 |
Price-to-Median-PS-Value ranked
lower than
98.53%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ASND:
1.52
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 0.78, Max: 31.63
Current: 1.52
|
| Earnings Yield (Joel Greenblatt) % | -3.02 |
Earnings Yield (Greenblatt) ranked
higher than
53.10%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ASND:
-3.02
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -27.8, Med: -10.2, Max: -2.64
Current: -3.02
|
More Statistics
| Revenue (TTM) (Mil) $ | 12.04 |
| EPS (TTM) $ | -3.77 |
| Beta | 1.13 |
| Volatility % | 65.98 |
| 52-Week Range $ | 53.21 - 133.96 |
| Shares Outstanding (Mil) | 47.09 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |
» More articles for ASND
Headlines
Log In